NDA 203389 · Horizon
Procysbi
Cysteamine Bitartrate · Oral
OrphanLast checked: Nov 19, 2026Latest source record: Feb 11, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Apr 30, 2013
Approved uses
3
Original approval plus efficacy supplements
Registered trials
33
8 Phase 3, 2 recruiting
FAERS reports
758
403 serious, 38 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 25, 2026.
PROCYSBI is indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older. PROCYSBI is a cystine-depleting agent indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older. ( 1 )
Mechanism: Cysteamine is an aminothiol that participates within lysosomes in a thiol-disulfide interchange reaction converting cystine into cysteine and cysteine-cysteamine mixed disulfide, both of which can exit the lysosome in patients with cystinosis.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 22, 2017 Supplement 20 · Efficacy · priority review OrphanLetterPediatric Written RequestPediatric Amendment 1
- Aug 14, 2015 Supplement 10 · Efficacy LabelLetter
- Apr 30, 2013 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLabelReviewPediatric Medical Review
2 products under this application
- PROCYSBI · CYSTEAMINE BITARTRATE EQ 25MG BASE · CAPSULE, DELAYED RELEASE, ORAL · Prescription
- PROCYSBI · CYSTEAMINE BITARTRATE EQ 75MG BASE · CAPSULE, DELAYED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cysteamine Bitartrate" as an intervention, any sponsor and status, largest first.
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
National Eye Institute (NEI)NIH
NCT00001213 · 328 participants · Start Apr 1986 · Primary completion Jul 2013
Drug: Cysteamine · For: Cystinosis
Sites: Bethesda, Maryland
Mylan LaboratoriesIndustry
NCT00002110 · 300 participants
Drug: Cysteamine; Zidovudine · For: HIV Infections
Sites: Tampa, Florida; New Orleans, Louisiana; Stony Brook, New York · 6 sites in all
- Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in ChildrenPivotal-lookingCompleted
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT01529268 · 169 participants · Start Jun 2012 · Primary completion Mar 2015
Drug: DR cysteamine bitartrate capsule · For: Nonalcoholic Fatty Liver Disease (NAFLD)
Sites: San Diego, California; San Francisco, California; Atlanta, Georgia · 10 sites in all
- Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal MelasmaPivotal-lookingStatus unknown
Cosmetique Active InternationalIndustry
NCT06278948 · 140 participants (planned) · Start Oct 6, 2023 · Primary completion Jun 2024
Drug: Group CYS · For: Melasma
Sites: Bangalore, India
- Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)Pivotal-lookingStatus unknown
University Hospital, AngersGovernment (non-federal)
NCT02101957 · 96 participants · Start Oct 2010 · Primary completion Jul 2015
Drug: RP103; Placebo · For: Huntington's Disease
Sites: Angers, France
NovaBiotics Ltd.Industry
NCT03000348 · 91 participants · Start Dec 2016 · Primary completion Apr 2018
Drug: Cysteamine; Placebo Oral Capsule · For: Cystic Fibrosis
Sites: Tucson, Arizona; San Francisco, California; Gainesville, Florida · 17 sites in all
- Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01197378 · 60 participants · Start Aug 27, 2010 · Primary completion Jun 26, 2017
Drug: Cysteamine Bitartrate Delayed-release Capsules · For: Cystinosis
Sites: San Francisco, California; Stanford, California; Atlanta, Georgia · 10 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- vomiting113
- nausea104
- eye irritation47
- abdominal pain upper32
- diarrhoea32
- abdominal discomfort30
- malaise28
- death25
- headache25
- product dose omission issue23
- illness22
- amino acid level increased21
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 2 |
| 2014 | 15 |
| 2016 | 3 |
| 2017 | 25 |
| 2018 | 93 |
| 2019 | 102 |
| 2020 | 116 |
| 2021 | 78 |
| 2022 | 38 |
| 2023 | 57 |
| 2024 | 130 |
| 2025 | 60 |
| 2026 | 39 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Procysbi (Cysteamine Bitartrate)
2024 spending
$38.0M
Beneficiaries
59
512 claims
Per beneficiary
$644,082
$174.39 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $37,076,777 |
| 2021 | $41,249,117 |
| 2022 | $43,346,345 |
| 2023 | $39,331,261 |
| 2024 | $38,000,864 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington's disease.
Verny C, Bachoud-Lévi AC, Durr A, et al. · Mov Disord 2017 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Targeted Therapies for Leigh Syndrome: Systematic Review and Steps Towards a 'Treatabolome'.
Tiet MY, Lin Z, Gao F, et al. · J Neuromuscul Dis 2021 · Systematic Review
- Alanine Aminotransferase and Gamma-Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis.
Newton KP, Lavine JE, Wilson L, et al. · Hepatology 2021 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- A systematic literature review of cysteamine bitartrate in the treatment of nephropathic cystinosis.
Medic G, van der Weijden M, Karabis A, et al. · Curr Med Res Opin 2017 · Systematic Review
- Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study.
Levin SW, Baker EH, Zein WM, et al. · Lancet Neurol 2014 · Clinical Trial, Research Support, N.I.H., Extramural
- A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety.
Langman CB, Greenbaum LA, Sarwal M, et al. · Clin J Am Soc Nephrol 2012 · Comparative Study, Randomized Controlled Trial
Sponsor: Amgen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.